PCSK9-IN-20
PCSK9-IN-20 (Compound 3i) is a PCSK9 inhibitor with an IC50 of 3.96 µM. PCSK9-IN-20 decreases PCSK9 and increases LDLR protein expression in vitro[1].
Product Specifications
CAS Number
2929219-77-0
UNSPSC
12352005
Target
PCSK9
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Neuroscience-Neuromodulation
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/pcsk9-in-20.html
Solubility
10 mM in DMSO
Smiles
O=S(C1=CC=C(C(NC2=NC3=CC=C(CN4CCN(C(OC(C)(C)C)=O)CC4)C=C3S2)=O)C=C1)(NCCC#N)=O
Molecular Formula
C27H32N6O5S2
Molecular Weight
584.71
References & Citations
[1]Zhixin Ma, et al. Identification of benzothiazoles as novel PCSK9 inhibitors. Bioorg Med Chem Lett. 2023 Nov 6:129542.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
bsm-41706M-PerCP 100 µL
Azurocidin/HBP Monoclonal Antibody, PerCP Conjugated
Sign In for Pricing
View Details 
K4721906 1.0 µg DNA
Cramp1l sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1)
Sign In for Pricing
View Details